Six-year Miyosmart follow-up shows sustained myopia management effect

Results from Hoya Vision Care’s six-year follow-up study on the Miyosmart spectacle lens have shown a sustained myopia management effect over time, with no rebound effect for patients who stopped the treatment.

The study looked at the progression of myopia in 90 children in Asia who wore the Miyosmart spectacle lens.

The results were presented at the Association for Research in Vision and Ophthalmology 2022 conference in the US, by Professor Carly Lam from the Centre for Myopia Research at The Hong Kong Polytechnic University.

The research is the longest study on myopia management spectacle lenses and builds on a three-year study and continuation of a two-year randomised controlled trial, published in the British Journal of Ophthalmology, which demonstrated the effectiveness of the lenses in slowing the progression of myopia in children aged between eight and 13.

The six-year follow-up study showed that the myopia management effect of the Miyosmart spectacle lenses for wearers is sustained over time.

The study also confirmed that patients who stopped wearing the Miyosmart spectacle lens demonstrated no rebound effects, when compared to the initial myopia rates of progression during either the two-year randomised control trial, or the general population.

Natalia Vlasak, global head of medical and scientific affairs at Hoya Vision Care, commented that the findings show that the myopia management effects were sustainable over time is “very exciting news,” and added that the study answered “another key question” regarding the potential for rebound, confirming there is no such effect if lens use is stopped.